Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer

Chune Yu1,7, Dan Luo2,7, Jing Yu1,7, Min Zhang1, Xiaobo Zheng1, Guangchao Xu3, Jiaxin Wang1, Huiling Wang1, Yufei Xu1, Ke Jiang4, Jie Xu5, Xuelei Ma6, Jing Jing1,5 and Hubing Shi1,5

© The Author(s) 2021

Oncogene (2022) 41:191–203; https://doi.org/10.1038/s41388-021-02077-w

INTRODUCTION
Colorectal cancer (CRC) is one of the most common malignancies, with the third highest incidence and death rate in both women and men in the United States [1]. Approximately 40% of CRCs harbor oncogenic KRAS mutations, mainly G12D, G12V, and G13D, which can sustainably activate the MAPK signaling pathway [2, 3]. Given the fact that KRAS mutations are often associated with poor prognosis in CRC patients [4], therapeutic regimens targeting KRAS or its signaling are regarded as one of the most desired strategies in clinics [5]. Although two small molecules, AMG510 and MRTX849, which target KRAS G12C have entered clinical trials, these inhibitors produced less profound activity in CRC than non-small cell lung cancer patients [6–10]. In addition, the KRAS G12C mutation accounts for only one to three percent of all CRC patients, which largely limits the potential populations who could benefit [2, 11]. Thus, a strategy that directly targets a broad spectrum of KRAS mutations remains challenging.

Since RAS can activate the MAPK pathway, which consists of a linear kinase cascade, blockade of downstream kinases, vertical repression of MEK, has previously been considered a promising strategy [12]. However, the results of clinical trials with MEK inhibitor (MEKi) were disappointing in CRC patients [13, 14]. The negative clinical outcome was attributed to the fact that blockading MEK released the negative feedback regulation of RTKs [15–17]. Upon activation, RTKs might reactivate the MAPK pathway or activate redundant pathways to confer resistance to MAPK inhibitors. Notably, multiple RTKs are attributed to this process, implying that attenuation of this adaptive resistance by targeting a single RTK may not be an effective strategy [8]. Therefore, identifying pivotal mediators in the negative feedback loop of the RTK pathway and providing combination therapy to overcome MEKi resistance are urgently needed.

Multiple high-throughput genome-wide screening approaches have been applied to unbiasedly identify critical genes that contribute to drug resistance in human cancers. Previously, RNA interference (RNAi) screening with shRNA library to knockdown targeted genes has been widely used [18, 19]. However, inefficient gene knockdown and off-target effects limited their applications [20]. Recently, the CRISPR-Cas9 library system with innovations in genome editing technology has provided an
alternative way to overcome these limitations. It has been used to identify genes that are essential for cancer cell survival, proliferation, and targeted drug resistance in vitro and in vivo [21–24]. Therefore, we performed genome-wide CRISPR/Cas9 knockout screening to identify the pivotal oncogenes contributing to overcoming MEKi resistance in CRC cells. Further, we performed co-targeting of MEK and PLK1 kinases to investigate its effect on CRC both in vitro and in vivo. Our findings will not only help clarify the mechanism of primary resistance to MEK-targeted therapy in CRC, but also provide a combinatorial regimen for clinical treatment.
RESULTS
RTK pathway mediates MEKi resistance in KRAS mutant colon cancer
To identify the critical driver genes involved in MEKi resistance, we designed a combination strategy with genome-wide CRISPR/Cas9 knockout library screening and transcriptomic analysis of KRAS-mutated cell lines (Fig. 1A). The model cell line HCT116 was selected, which exhibited a relatively medium drug tolerance capability for MEKi in a short-term cell proliferation assay. The IC50 was around 3.6 µM (Supplementary Fig. S1A). To maintain an

Fig. 2  GRB7 was the determinant in the RTK pathway for MEKi resistance. A Scatter plot showing the genes that were enriched in the RTK pathway. The top ten downregulated genes based on log2(fold change) are represented. The size of the point represents the number of identified downregulated sgRNA sequences for each gene. B The sgRNAs targeting GRB7 were consistently depleted in AZD6244-treated cells. The Student's t test was used to determine the p value. C Boxplot of GRB7 expression in normal and tumor tissues of colon cancer patient samples with or without the BRAF mutation and KRAS mutations from TCGA-COAD. The Wilcoxon test was used to determine the p value. D, E Representative immunohistochemical images of GRB7 staining in normal and tumor tissues from colon cancer patients. Scale bar, 200 µM. F Quantification of (D). Data represented as mean ± SD (n = 14). The Wilcoxon test was used to determine the p value. G Kaplan-Meier survival analysis of the association of GRB7 levels with disease-free survival (DFS) of colon cancer patients. Patients were divided into low or high groups according to the expression of GRB7. The log-rank test was used to determine the p value. H GRB7 mRNA expression was increased in AZD6244-treated cells. Datasets were from Fig. 1C, D. The Wilcoxon test was used to determine the p value. Batch effects between different datasets were removed by ComBat. I Cell cytoplasm/nucleus fractionation and western blot analysis to show GRB7 translocation with AZD6244 treatment. HCT116 cells treated with AZD6244 were fractionated into nuclear and cytoplasmic fractions at the indicated time points. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001; TCGA-COAD The Cancer Genome Atlas Colon Adenocarcinoma.
approximate 500× sgRNA coverage, 200 million cells stably expressing Cas9 were infected with the human GeCKO library two-vector lentivirus system. The single gene knockout in each cell was strictly controlled by adjusting the infective MOI to close to 0.3. After puromycin selection, cells were treated with DMSO or AZD6244 for 7 days. Subsequently, genomic DNA encompassing sgRNA was extracted and assessed by PCR amplification and high-throughput sequencing (Supplementary Table S1). The quality and selective enrichment number of sgRNA reads showed comparable patterns between the DMSO-treated group and the AZD6244-treated group, indicating that no obvious bias selection was observed in the screening process (Supplementary Fig. S1B, C).

Fig. 3  **GRB7 is sufficient for MEKi resistance in KRAS mutation colon cancer cells.** A Clonogenic assay showing that knockdown of GRB7 with shRNAs enhanced response to MEKi. B Short-term survival curves identifying that knockdown of GRB7 increased the sensitivity of MEKi. Results are shown relative to DMSO-treated controls (mean ± SD, n = 5; dashed line, 50% inhibition). C–F Knockdown of GRB7 significantly induced apoptosis upon AZD6244 treatment in HCT-116 (C, D) and SW480 (E, F). Cells were treated with AZD6244 for 48 h (HCT116) or 24 h (SW480). Data represented as mean ± SD (n = 3). G–I Clonogenic assay showing that GRB7 overexpression conferred resistance to AZD6244. (H) Quantification of HCT116, (I) Quantification of SW480. Data represented as mean ± SD (n = 3). J, K Induction of anti-apoptosis upon overexpression of GRB7 in HCT116. K Quantification of (J). Data represented as mean ± SD (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
Theoretically, genes whose deletion causes MEKi lethality should preferably be observed in DMSO-treated cells as opposed to AZD6244-treated cells, thus providing a novel combination treatment. Considering the off-target effects of sgRNA, we selected genes with at least three downregulated sgRNAs in AZD6244-treated cells, as preliminary candidates. In parallel, we profiled the transcriptome of HCT116 cells in the presence or absence of AZD6244 for 7 days. We assumed that the genes driving resistance were transcribed effectively in AZD6244-treated cells. Thus, the preliminary identified genes with a TPM value of no less than 10 (moderate expression level) were identified as confident candidate genes [25]. Based on this
strategy, we identified a series of sgRNAs targeting 1846 genes, which were significantly depleted in AZD6244-treated cells compared to DMSO-treated cells (Supplementary Fig. S1D). The results of Gene Ontology (GO) enrichment analysis showed that these genes were predominantly distributed in some pathways, such as the transmembrane receptor protein tyrosine kinase signaling (RTK pathway), the NF-κB pathway, and the regulation of extrinsic apoptotic pathway (Fig. 1B). Transcriptomic analysis of CRC cells revealed that the expression patterns of RTK genes were significantly disrupted upon MEKi treatment (Fig. 1C, D). In line with this cellular sequencing data, similar phenotypes were observed in another independent experiment of CRC organoids treated with MEKi (Supplementary Fig. S1E). Furthermore, gene set enrichment analysis (GSEA) also demonstrated that expression of RTK pathway genes was significantly upregulated in CRC cells treated with MEKi (Fig. 1E). To further confirm this result, we performed the western blot analysis of proteins in the RTK pathway upon MEKi treatment (Supplementary Fig. S1F). Phosphorylation levels of EGFR, MET, FAK, and AKT were significantly upregulated by AZD6244 treatment in CRC cell lines (Fig. 3C). Moreover, GRB7 knockdown synergistically induced cell apoptosis with AZD6244 treatment for 24 and 48 h in CRC cell lines (Fig. 3F, Supplementary Fig. S3F). Apoptosis analysis in A549 (lung cancer) and CFPAC-1 (pancreatic cancer) cells was performed to determine whether GRB7 mediates MEKi resistance in other RAS-driven cancer types. The mechanism of primary resistance in these cells was reported to be activation of the RTK-mTOR signaling pathway [28]. The results showed that GRB7 knockdown further promoted apoptosis when combined with AZD6244 in A549 and CFPAC-1 cells (Supplementary Fig. S3G).

In addition to the loss-of-function validation, we also tested the gain of function by overexpressing GRB7 in CRC model cell lines. The proliferation of HCT116 and SW480 cells, which were infected with lentivirus encoding FLAG-tagged GRB7, was evaluated in the presence of the MEKi (Supplementary Fig. S4A). The results of the clonogenic assay demonstrated that overexpression of GRB7 significantly promoted resistance to AZD6244 (Fig. 3G–I). In addition, overexpression of GRB7 also relieved cell apoptosis induced by high doses of AZD6244 in HCT116 cells (Fig. 3J, K). Inspired by these results, we sought to investigate whether GRB7 overexpression could also confer MEKi resistance in CRC cells with the BRAF mutation, another genetic lesion leading to sustained activation of the MAPK pathway [29]. Similarly, ectopic expression of GRB7 in HT29 and WiDr cells, which harbor the V600E BRAF mutation, also significantly promoted resistance to AZD6244 in the long-term clonogenic assay (Supplementary Fig. S4B–E). Taken together, these results demonstrate that GRB7 mediates MEKi resistance in CRC cells with KRAS or BRAF mutations.
GRB7 mediates the activation of the RTK downstream pathway to render MEKi resistance in CRC cells

To investigate whether GRB7 confers resistance to MEKi by mediating the RTK pathway, we characterized the activation status of effectors within this pathway, including FAK, STAT3, AKT, mTOR, 4EBP1, and ERK in CRC cell lines with or without GRB7 knockdown in the presence of MEK inhibitors (Fig. 4A and Supplementary Fig. S4F). The western blot results showed that GRB7 knockdown significantly attenuated the phosphorylation levels of FAK, STAT3, AKT, mTOR, and 4EBP1, although some of them, such as FAK and STAT3, were compensatorily evoked by MEK inhibition. Interestingly, GRB7 knockdown slightly increased the level of p-ERK,
indicating compensatory feedback signaling. In line with previous apoptosis assays, the level of cleaved PARP induced by GRB7 knockdown was further promoted by MEKi in HCT116 and SW480 cells (Fig. 4A and Supplementary Fig. S4F). In parallel, we ectopically overexpressed GRB7 and detected the downstream activation of RTK. The western blot results showed that the phosphorylations of AKT and 4EBP1 increased upon GRB7 overexpression in CRC cells (Fig. 4B and Supplementary Fig. S4G). These results suggest that GRB7 potently mediates the activation of the RTK downstream pathway. To further investigate whether GRB7 is essential for the activation of RTK pathways, we challenged RTKs with their ligands and probed the activation of downstream effectors upon perturbation of GRB7. It has previously been reported that c-MET and EGFR were the predominant activated RTKs upon AZD6244 treatment in HCT116 cells [17], therefore we chose their ligands HGF and EGF to stimulate c-MET and EGFR, respectively (Fig. 4C–F). The phosphorylation levels of FAK, AKT, STAT3, and 4EBP1 were reversely attenuated by GRB7 knockdown which was upregulated by stimulation with HGF or EGF. These results further strengthen the conclusion that GRB7 mediates activation of the RTK pathway.

Since GRB7 contains an SH2 domain, we speculated that GRB7 mediates the RTK pathway by transducing signaling through direct interactions with the heterologous and dynamic expression pattern of RTK, which could change the interaction between GRB7 and two representative receptors, EGFR and MET. The results of the co-IP experiment indicated that GRB7 formed a complex with EGFR and MET in HCT116 cells (Fig. 4G). To further confirm this direct interaction between RTKs and GRB7, the subcellular distribution of GRB7, upon stimulation with HGF, a MET ligand, was investigated. Similar to EGFR [30], HGF stimulation facilitated the export of GRB7 from the nucleus to the cytoplasm (Fig. 4H, I), which might be a common approach to the regulation of GRB7 signaling by growth factors. Collectively, these data strengthen the conclusion that GRB7 mediates the activation of the RTK signaling pathway by direct interaction, which sufficiently confers MEKi resistance in CRC cells.

GRB7 mediates the RTK pathway through PLK1 recruitment

To further elucidate the molecular mechanism of the GRB7-mediated RTK pathway, we performed immunoprecipitation coupled with mass spectrometry (IP-MS). Potential GRB7-interacting proteins were co-precipitated with anti-FLAG antibody-conjugated beads and subsequently subjected to MS analysis. A total of 57 GRB7-interacting proteins were enriched at least threefold in HCT116 cells expressing FLAG-GRB7 compared to that in control cells (Supplementary Table S3). Since GRB7 mediates intrinsic function in CRC tumor tissues, the proteins mediating GRB7 signaling should be enriched in tumor tissue as opposed to normal tissue. Following this assumption, we found that polo-like kinase-1 (PLK1) was the top-ranked protein, which showed both significant upregulation in CRC tissues compared to normal tissues, and abundant MS identity peptides (Fig. 5A and Supplementary Fig. S5A–D). In line with this assumption, IHC analysis of patient samples showed that PLK1 expression in CRC tumor biopsies was much higher than that in normal tissues (Fig. 5B, C). In addition, regulatory associated protein of mTOR complex 1 (RPTOR), which is a downstream substrate of PLK1 in the GRB7-binding complex was also found. The interactions between PLK1 or RPTOP and GRB7 were validated by co-IP assay. As expected, the results of the co-IP assay with the anti-FLAG antibody showed that GRB7 formed a complex with PLK1 and RPTOR in HCT116 and SW480 cells expressing FLAG-GRB7 (Fig. 5D, Supplementary Fig. S5E). In addition, GRB7 also interacted with phosphorylated PLK1, implying that GRB7 may promote the function of PLK1. A reverse immunoprecipitation assay with PLK1 antibody further confirmed the existence of a complex consisting of GRB7, PLK1, RPTOR, and mTOR (Fig. 5E). Inspired by the interaction between GRB7 and PLK1, we speculated that PLK1 may potentially mediate the RTK-GRB7 signaling pathway. GRB7 was overexpressed in HCT116 cells in order to test this hypothesis. The overexpressed GRB7 was mobilized to the membrane, and a clear co-localization between GRB7 and PLK1 was observed throughout the process (Fig. 5F). Moreover, knockdown of GRB7 with shRNAs downregulated PLK1 by ~40% at both protein and mRNA levels in HCT116 and SW480 cells, suggesting that the regulation was not limited to subcellular localization (Fig. 5G and Supplementary Fig. S5F).

To investigate whether GRB7 regulates the RTK pathway through the recruitment of PLK1, we performed an immunoprecipitation assay with PLK1 antibody in GRB7 overexpressed HCT116 cells and probed the downstream kinases in the RTK pathway (Fig. 5H). The interactions of PLK1 and its downstream kinases (FAK, STAT3, and AKT) were enhanced when GRB7 was overexpressed. Then, PLK1 was knocked down with shRNAs and the downstream effectors in the RTK pathway were evaluated in the presence of AZD6244 (Supplementary Fig. S5G, H). Similar to the results obtained with the GRB7 knockdown, silencing of PLK1 by shRNAs attenuated the phosphorylation levels of FAK, STAT3, AKT, mTOR, and 4EBP1, but slightly increased the phosphorylation of ERK when combined with MEKis (Fig. 5I and Supplementary Fig. S6A, B), suggesting that PLK1 mediated MEKi-induced RTK/GRB7 pathway activation. Consistent with the results of the shRNA
Fig. 6  Combined genetic or pharmacologic inhibition of PLK1 and MEKi treatment promoted apoptosis in KRAS mutant colon cancer cells. A, B Knockdown of PLK1 by shRNAs induced apoptosis upon AZD6244 treatment in HCT116. B Quantification of (A). Data represented as mean ± SD (n = 3). C, D Apoptosis assay showing that BI-2536 sensitized HCT116 cells to AZD6244. D Quantification of (C). Data represented as mean ± SD (n = 3). E HCT116 cells infected with shRNA targeting GRB7 or vector control, then treated with or without BI-2536 in the presence of 1 μM AZD6244 for 48 h. Data represented as mean ± SD (n = 3). F HCT116 cells infected with vector control, Flag-GRB7, shRNA targeting PLK1, or the combination of both, then treated with 10 μM AZD6244 for 48 h. Apoptosis was detected by annexin V/PI staining. Data represented as mean ± SD (n = 3). G–I Representative phase-contrast and immunofluorescence staining images of HCT116 treated with DMSO, AZD6244, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. H Quantification of spheroid area. J–L Representative phase-contrast and immunofluorescence staining images of SW480 treated with DMSO, GSK, BI-2536, or the combination of both for 8 days in 3D culture system (CaM: green; PI: red). Scale bar, 100 μM. K Quantification of spheroid number. L Quantification of spheroid number. *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001.
In summary, our data strongly demonstrated that upregulation of GRB7 conferred MEKi resistance in CRC cells with KRAS mutations by mediating RTK signaling through the recruitment of PLK1.

Combination inhibition of PLK1 and MEK promotes cell apoptosis in KRAS mutant colon cancer cells

We then investigated the synergistic efficacy of combining PLK1 and MEK inhibition in 2D- and 3D-CRC models. The results showed that knockdown of PLK1 alone induced apoptosis, which was further improved with AZD6244 treatment in HCT116 and SW480 cells (Fig. 6A, B, and Supplementary Fig. S7A, B). Similar results were observed in CRC cells with PLK1 knockdown followed by GSK treatment (Supplementary Fig. S7C). In line with the results of GRB7 inhibition, knockdown of PLK1 also significantly promoted apoptosis of A549 and CFPAC-1 cells in the presence of AZD6244 (Supplementary Fig. S7D). To further verify the results of RNAi, we interrupted the function of PLK1 with the small molecular inhibitor, BI-2536. Similarly, combination treatment with BI-2536 and AZD6244 synergistically induced CRC cell apoptosis in HCT116 and SW480 cells after 48 h (Fig. 6C, D, and Supplementary Fig. S7E, F). Next, we further investigated whether GRB7-mediated MEKi resistance was dependent on PLK1. CRC cells were treated with BI-2536 on top of GRB7-knockdown in the presence of AZD6244 (Fig. 6E and Supplementary Fig. S7G). GRB7 knockdown or BI-2536 improved cell apoptosis. However, the combination of these two treatments did not further enhance cell apoptosis, suggesting that GRB7 and PLK1 might not play redundant roles. In addition, apoptosis and clonogenic assays showed that knockdown of PLK1 abolished the drug tolerance derived from GRB7 overexpression in CRC cells (Fig. 6F and Supplementary Fig. S7H-J).

Furthermore, synergistic growth inhibition was further validated using a multicellular spheroid three-dimensional (3D) model. HCT116 and SW480 cells were cultured in Matrigel and treated...
with DMSO, MEKi, PLK1i, or their combination for 8 days. One representative sphere was tracked continually and photographed at the indicated time points. Although MEKi or BI-2536 treatment partially suppressed CRC spheroid growth, BI-2536 treatment significantly improved the therapeutic effects of MEKis. The combination regimen not only significantly inhibited cell proliferation in spheroid numbers and sizes, but also induced apoptosis in HCT116 and SW480 cells (Fig. 6G–L, Supplementary Fig. S8A–F). Encouraged by the in vitro results, we evaluated the combination efficacy in the HCT116 xenograft model (Fig. 7A). Although both AZD6244 and BI-2536 significantly slowed tumor growth, the efficacy of the combination regimen of AZD6244 plus BI-2536 was more potent than that of AZD6244 or BI-2536 alone (Fig. 7B–E). Meanwhile, a clear synergistic effect of the combination treatment was observed on day 26 (Fig. 7C). In line with the tumor growth inhibition, IHC staining showed that the combination AZD6244 and BI-2536 led to a super-additive reduction in Ki67 protein levels (Fig. 7F, G). Moreover, the number of Tunel-positive cells was significantly increased with the combination treatment (Fig. 7F, H). Taken together, these results demonstrate that the addition of BI-2536 could improve the therapeutic efficiency of MEKi.

Furthermore, similar to the inhibition of PLK1, knockdown of RPTOR also sensitized HCT116 and SW480 cells to AZD6244 (Supplementary Fig. S9A–C). Taken together, our data illustrate the RTK/GRB7/PLK1 signaling pathway (Fig. 8) and highlight the synergistic combination regimen of BI-2536 and MEKi in CRC treatment.

**DISCUSSION**

The feedback activations of redundant signaling mediated by RTKs were considered to confer MEKi resistance in previous studies [17, 28, 31, 32]. Recently, RTK-driven feedback activation also conferred resistance to KRAS G12C inhibitors [8], suggesting that the combination of RTK and MAPK-targeted therapy is a promising regimen. Indeed, the heterogeneity of RTK/RTK ligand activation renders combination therapies with MAPKi and RTKi unfeasible [33]. Combination treatment with EGFRi and MEKi produced limited antitumor efficacy in CRC patients [34]. The preexistence or activation of multiple RTKs, except for EGFR-mediated redundant pathways, may be the predominant reason. Therefore, identification of common mediators in the RTK pathway might be critical for the development of novel therapeutic strategies. Herein, we report that GRB7 plays a pivotal role in MEKi resistance in CRC cells with KRAS mutations by performing unbiased genome-wide CRISPR/Cas9 knockout screening, which is a powerful approach to identifying synergistic drug targets [35]. Knockdown of GRB7 induced cell apoptosis and re-sensitized CRC cells to MEKi by attenuating the efficient activation of the RTK pathway. However, ectopic expression of GRB7 was able to activate this signaling pathway, thus protecting CRC cells from MEKi-induced apoptosis and promoting cell survival when the MEK pathway was suppressed. Notably, we observed similar results in KRAS mutant lung and pancreatic cancer cells, implying that GRB7 plays a critical role in RAS-driven cancer cells in the presence of MEKi.

GRB7 targeting inhibits ovarian cancer tumor growth through the ERK inhibition [36]. Interestingly, p-ERK levels were slightly increased in both GRB7 knockdown and GRB7-overexpressing cells (Fig. 4A, B). We speculate that this is due to the DUSP family-mediated compensatory network and further research needs to demonstrate the role of GRB7 in the regulating DUSPs. The inhibition of JNK, which is downstream of GRB7, displays synergy with the MEKi [37, 38].

GRB7 inhibition, either alone, in combination chemotherapy [39, 40], or in combination targeted therapy improves the efficiency of antitumor therapy. However, the detailed regulatory mechanism of GRB7 needs to be illustrated, because effective inhibitors targeting GRB7 are unavailable in the clinic. Here, we found that GRB7 maintained RTK signaling via PLK1 in CRC cells with KRAS mutations. GRB7 overexpression promoted the cytoplasmic localization of PLK1, which might be attributed to the nuclear export complex consisting of GRB7 and its function as a translational regulator [30]. Similar to the knockdown of GRB7, inhibition of PLK1 with shRNAs and inhibitor, attenuated the GRB7 oncogenic signals, leading to cell apoptosis in the presence of MEKi. In addition, extra BI-2536 did not further enhance cell apoptosis induced by GRB7 knockdown in the presence of MEKi. PLK1 signaling has also been reported to confer resistance to PI3K inhibitors by Tie-FGFR1-STAT3 [41]. However, we observed that inhibition of PLK1 with shRNAs or inhibitor significantly impaired the phosphorylation of STAT3, which was induced by AZD6244.

PLK1 was identified as a lethal kinase in RAS-mutated CRC, and the potent efficacy of PLK1 inhibitor has been well demonstrated in vitro and in vivo [42]. Recently, the PLK1 inhibitor onvansertib was fast tracked to treat patients with KRAS mutations in CRC by the FDA. Our study found that the PLK1 and MAPK pathway synergistically controlled cell proliferation and apoptosis. The combination of PLK1 and MEKis showed more potent efficacy in suppressing cell proliferation in 2D and 3D cellular models, as well as in xenograft animal model. We also noticed that an additional
MEKi significantly improved the efficiency of the PLK1 inhibitor by diminishing the dose from 50 \( \text{mg/kg} \) (Fig. 7A–C). Furthermore, we showed that RPTOR, PLK1, and GRB7 formed a complex, and their knockdown synergistically inhibited CRC cell proliferation with MEKi, consistent with the fact that activation of the mTOR pathway plays a pivotal role in RTKi resistance [43]. Recently, PLK3, another member of the PLK1 family, was reported to confer resistance to the MAPK pathway inhibitor in melanoma [44]. Thus, the detailed function of the PLK1 family in the regulation of MEKi resistance in CRCs needs to be further investigated.

In conclusion, our data illustrate that the RTKs-GRB7-PLK1 signaling pathway plays a pivotal role in resistance to MEKis and a combination inhibition of this axis and MEK provides a promising strategy to cure CRC patients with KRAS mutation (Fig. 8). Moreover, lung and pancreatic cancer cells with KRAS mutation were also sensitive to GRB7-PLK1 inhibition in combination with MEKi. This provides inspiration for novel treatment combinations for refractory tumors with KRAS mutation.

**MATERIALS AND METHODS**

**Cell culture**

HT29, WiDr, HCT116, LS174T, and HEK293T; SW480 and A549; and CFPAC-1 cells were cultured in DMEM; RPMI; and IMDM, respectively, in a humidified 5% CO2 incubator at 37 °C. The culture media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cell lines were purchased from ATCC and verified to be free of mycoplasma.

**Cell apoptosis**

Cell apoptosis assays were performed as previously described [45]. Cells were stained using the Annexin V Apoptosis Detection Kit (4B Biotech) and analyzed using CytoFLEX (Beckman Coulter). The early apoptotic cell population (Annexin V+/PI-) and late apoptotic cell population (Annexin V+/PI+) were combined to obtain the total proportion of apoptotic cells.

**DATA AVAILABILITY**

All data generated or analyzed during this study are included in this published article and its supplementary information.

**REFERENCES**

1. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterfly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. CA: Cancer J Clin. 2020;70:145–64.
2. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 2009;205:858–62.
3. Sveen A, Koptez S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020;17:11–32.
4. Fiara O, Buchler T, Mohelnikova-Duchonova B, Melichar B, Matejka VM, Holubec L, et al. G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. Tumour Biol. 2016;37:6823–30.
5. Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the KRAS pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) Inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 2020;10:54–71.
6. Hong DS, Fakhri MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207–17.
7. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med. 2014;6:224ra26.
8. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600E-mutant colorectal cancer. J Clin Oncol. 2015;33:4023–31.
9. Infante JR, Fehrer LA, Falchook GS, Nallapareddy S, Gordon MS, Beccara C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:773–81.
10. Kirouac DC, Schafer G, Chan J, Merchant M, Orr C, Huang SA, et al. Clinical responses to ERK inhibition in BRAF(V600E)-mutant colorectal cancer predicted using a computational model. NPJ Syst Biol Appl. 2017;3:14.
11. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012;2:227–35.
12. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep. 2014;7:1940–55.
13. Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 2014;7:86–93.
14. Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Gremmarm W, et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell Rep. 2014;8:1475–83.
15. Housden BE, Perrimon N. Comparing CRISPR and RNAi-based screening technologies. Nat Biotechnol. 2016;34:621–3.
16. Liang J, Zhao H, Diplas BH, Liu S, Liu J, Wang D, et al. Genome-Wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition. Cancer Res. 2020;80:510–23.
17. Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DW, et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. Nat Commun. 2019;10:4681.
18. Hart T, Chandrashekar M, Aregger M, Steinhardt Z, Brown KR, MacLeod G, et al. High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer vulnerabilities. Cell. 2015;163:1515–26.
19. Joung J, Konermann S, Gootenberg J, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knock out and transcriptional activation screening. Nat Protoc. 2017;12:828–63.
20. Liu Y, Liu K, Yin L, Yu Y, Qi J, Shen WH, et al. H3K4me2 functions as a repressive epigenetic mark in plants. Epigenetics Chromatin. 2019;12:94.
21. Yu C, Liu X, Yang J, Zhang M, Jin H, Ma X, et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front Immunol. 2019;10:990.
22. Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo P, et al. MEK162 for patients with advanced melanoma harbouring NRAS or V600E BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249–56.
23. Sulahian R, Kwon JJ, Walsh KH, Pailier E, Bosse TL, Thaker M, et al. Synthetic lethal interaction of SHOC2 depletion with MEK inhibition in RAS-driven cancers. Cell Rep. 2019;29:118–34. e8.
24. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene (2022);41:191 – 203.
AUTHOR CONTRIBUTIONS

HS conceived the project. CY and DL performed the majority of the experiments and analyzed the data. JY performed bioinformatics analysis. MZ, GX, JW, HW, XZ, and YX performed some experiments and contributed to the data analysis. CY and HS wrote the manuscript. JY, DL, KJ, XM, and JJ assisted in writing. All authors discussed the results, provided feedback, and reviewed the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ETHICAL APPROVAL

Human CRC tissues were obtained from West China Hospital with informed consent and were approved by the Institutional Ethics Committee of Sichuan University. All animal experiments were performed according to protocols approved by the Ethics Review Committee of Animal Experimentation of Sichuan University.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41388-021-02077-w.

Correspondence and requests for materials should be addressed to Jing Jing or Hubing Shi.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

ACKNOWLEDGEMENTS

We are also grateful to Li Chai and Yan Wang (Core Facility of West China Hospital) for their technical assistance. This work was funded by the National Natural Science Foundation of China (Nos. 81773752, 81902793, 81803574, 82172634, 31801143), the National Key Research and Development Program of China (No. 2016YFC0906000 [2016YFC0906003]), Key Program of the Science and Technology Bureau of Sichuan (No. 2021YJ08007), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYYC20013), Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma, and China Postdoctoral Science Foundation (2019M653430).

C. Yu et al.